IMAC Holdings announces VUMC collaboration for breast cancer biomarker RPPA profiling; issues $84K discounted note

IMAC Holdings, Inc.

One-year research collaboration with Vanderbilt University Medical Center; VUMC supplies 80 FFPE breast-cancer samples, Ignite performs RPPA analysis.
Ignite receives exclusive option to negotiate a worldwide license to jointly developed IP; each party bears own costs.
Issued $84,000 promissory note for $60,000 purchase price; unsecured, matures December 24, 2025.
Initial data packages expected within 2 months of sample receipt; collaboration aims to identify immunotherapy response biomarkers.

item 1.01item 2.03item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.